Bio-path Holdings, INC

Bio-Path Holdings announces strategic shifts including a new Series B Preferred stock, a pivot to cryptocurrency treasury management, and engagement of an advisor for biotech IP divestiture.

Bio-Path Holdings, Inc. disclosed significant strategic repositioning, including a digital asset treasury initiative and the potential acquisition of a substantial legal judgment.

Bio-Path Holdings, Inc. announced a shift in voting control to its CEO's advisory firm, plans for corporate domestication, and efforts to restart drug trials amid financial restructuring.

Bio-Path Holdings announced a board resignation and is actively seeking financing to support a company turnaround, warning of going concern risks if capital is not secured.

Bio-Path Holdings, Inc. announced the appointment of Vikram Grover as President, Chief Executive Officer, and Chief Financial Officer, alongside changes to its Board of Directors.

Bio-Path Holdings, Inc. has dismissed Ernst & Young LLP as its independent registered public accounting firm, effective August 13, 2025.

Bio-Path Holdings reports significant operational and financial challenges in its Q1 2026 Form 10-Q, including an operational pause, employee furloughs, and a continued going concern warning.

Bio-Path Holdings reported a significant accumulated deficit and $0 cash, leading to an operational pause and employee furloughs, while continuing to seek critical financing.

Bio-Path Holdings, a clinical-stage oncology and obesity drug developer, announced an operational pause and furloughed most employees due to critical capital constraints, raising substantial doubt about its ability to continue as a going concern.

Bio-Path Holdings reports a net loss of $2.9 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Bio-Path Holdings reported its Q3 2024 financial results, provided updates on its clinical trials, and addressed its ongoing efforts to regain compliance with Nasdaq listing requirements.

Bio-Path Holdings announced positive interim results from its Phase 2 clinical trial for prexigebersen in AML and secured $7.2 million in financing during the second quarter of 2024.

Bio-Path Holdings' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical programs, including progress in AML, lymphoma, solid tumors, and its newly initiated obesity program.

Bio-Path Holdings announces positive interim results from its Phase 2 AML clinical trial and provides updates on its other drug candidates.

Director Aline Sherwood acquired options to purchase 2,000 shares of Bio-Path Holdings stock at $1.55 per share.

Director Paul Aubert acquired options to purchase 2,000 shares of Bio-Path Holdings stock on July 30, 2024.

Heath Cleaver, a director at Bio-Path Holdings, acquired options to purchase 2,000 shares of common stock at $1.55 per share on July 30, 2024.

Director Douglas P. Morris acquired options to purchase 3,537 shares of Bio-Path Holdings common stock on July 30, 2024.

Peter Nielsen, President, CEO, and CFO of Bio-Path Holdings, Inc., reports the acquisition of options to purchase 25,000 shares of common stock.

Bio-Path Holdings is seeking stockholder approval for several key proposals at its upcoming annual meeting, including the election of directors, ratification of auditors, an amendment to the stock incentive plan, a reverse stock split, and approval for the issuance of more than 20% of common stock pursuant to a private placement.

Bio-Path Holdings is convening its 2024 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, an amendment to the stock incentive plan, and the approval of recent equity issuances.

Bio-Path Holdings is seeking to raise capital through a public offering of common stock and warrants, aiming to fund working capital and general corporate purposes.

Bio-Path Holdings is seeking to raise capital through a public offering of common stock and warrants, while continuing to advance its clinical-stage oncology and obesity-focused drug candidates.

Bio-Path Holdings is registering the resale of up to 483,750 shares of its common stock, issuable upon the exercise of warrants previously issued in private placements.

Bio-Path Holdings files an amendment to its Form S-1 registration statement primarily to include an exhibit related to legal opinion on the securities being registered.

Bio-Path Holdings, Inc. plans to offer up to 1,152,073 shares of common stock, pre-funded warrants, and common warrants to purchase up to 2,304,146 shares of common stock.

Bio-Path Holdings aims to raise capital through a public offering of common stock, pre-funded warrants, and common warrants.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Bio-Path Holdings, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a 9.99% beneficial ownership stake in Bio-Path Holdings, Inc. as of December 31, 2024, held for investment purposes.